改良疾病累计评分表在多西他赛联合顺铂化疗中的应用  

Application of modified cumulative illness rating scale in chemotherapy of docetaxel and cisplatin regimen

作　　者：严文辉[1] 彭新茂[1] 杨洲[1] 

机构地区：[1]湖南省脑科医院,湖南省第二人民医院肿瘤科,长沙410007

出　　处：《国际病理科学与临床杂志》2009年第2期111-114,共4页Journal of International Pathology and Clinical Medicine

摘　　要：目的:应用改良疾病累计评分表(modified cumulative illness rating scale,MCIRS)评价合并症,观察晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者多西他赛联合顺铂化疗毒副反应发生率。方法:选择NSCLC患者60例,采用MCIRS评估合并症,根据MCIRS评分、年龄及KPS分层研究多西他赛联合顺铂化疗毒副反应发生率。结果:60例NSCLC患者MCIRS评分为2～20(9.250±3.917)分。其化疗毒副反应胃肠道反应、骨髓抑制、疲劳及脱发的发生率随MCIRS评分的升高而增高,差异具有统计学意义(P<0.05);随年龄增加和KPS评分降低而略增高,但无统计学意义(P>0.05)。结论:MCIRS能较好地评价晚期非小细胞肺癌患者合并症,化疗毒副反应发生率随MCIRS评分的升高而增高。Objective To observe the incidence of chemotherapy toxicity of docetaxel and cisplatin regimen using the modified cumulative illness rating scale （MCIRS） to investigate the distribution of comorbidity in patients with the advanced non-small cell lung cancer （NSCLC）. Methods A total of 60 NSCLC patients was selected. Comorbidity was assessed with the MCIRS. The patients were stratified according to the score of MCIRS, age and karnofsky performance score （KPS） to study the incidence of chemotherapy toxicity of Docetaxel and Cisplatin regimen. Results The scores of MCIRS of sixty patients with NSCLC varied from 2 to 20（9. 250 ±3. 917）. With the increase of MCIRS score, the incidence of the toxicities of gastrointestinal, bone marrow, fatigue and hair losing were significantly increased in sixty patients who accepted chemotherapy. There were no changes in the incidence of toxicity when stratified by age or KPS. Conclusion MCIRS is a validated tool that can be used to evaluate comorbidity in patients with the advanced NSCLC. With the increase of MCIRS score, the occurrence rates of the toxicities were increased in the patients who accepted chemotherapy.

关 键 词：改良疾病累计评分表 非小细胞肺癌 合并症 化学治疗 

分 类 号：R734.2[医药卫生—肿瘤]